New combo aims to shrink rectal tumors before surgery
NCT ID NCT07509424
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a short course of radiation followed by three drugs (disitamab vedotin, sintilimab, and capecitabine) can completely eliminate tumors in people with advanced HER2-positive rectal cancer. About 29 adults aged 18-75 will receive the treatment before surgery. The goal is to see how many patients have no cancer left at the time of surgery or on follow-up scans.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital nurse companion: could an app ease the burden of chronic illness?
- Which rectal cancer surgery preserves quality of life better? a study investigates
- AI as a surgical Co-Pilot: predicting difficulty in rectal cancer
- Can AI learn to grade endoscopy quality from video?
- Can precision protons spare rectal cancer patients from harsh side effects?
- A new radiation combo may spare the rectum in early cancer